TY - JOUR
T1 - Brain Injury and Development in Preterm Infants Exposed to Fentanyl
AU - McPherson, Christopher
AU - Haslam, Matthew
AU - Pineda, Roberta
AU - Rogers, Cynthia
AU - Neil, Jeffrey J.
AU - Inder, Terrie E.
N1 - Publisher Copyright:
© 2015, © The Author(s) 2015.
PY - 2015/12/1
Y1 - 2015/12/1
N2 - Background: Fentanyl is commonly used in preterm infants. Relatively little is known regarding the neurodevelopmental outcomes of preterm infants exposed to fentanyl. Objective: To investigate the association between cumulative fentanyl dose and brain injury and diameters in a cohort of preterm infants. Methods: Data on demographics, perinatal course, and neonatal course, including total fentanyl exposure prior to term equivalent age, were retrospectively evaluated for 103 infants born at ≤30 weeks gestational age (mean gestational age 26.9 ± 1.8 weeks) who underwent magnetic resonance imaging at term equivalent age. Magnetic resonance images were evaluated for brain injury and regional brain diameters. Developmental testing was conducted at term equivalent and 2 years of age. Results: Seventy-eight infants (76%) received fentanyl (median cumulative dose 3 µg/kg, interquartile range 1-441 µg/kg). Cumulative fentanyl dose in the first week of life correlated with the incidence of cerebellar hemorrhage after correction for covariates (odds ratio 2.1, 95% confidence interval 1.1-4.1). Cumulative fentanyl dose before term equivalent age correlated with reductions in transverse cerebellar diameter after correction for covariates, including the presence of cerebellar hemorrhage (r = 0.461, P = 0.002). No correlation was detected between cumulative fentanyl dose and development at 2 years of age. Conclusions: Higher cumulative fentanyl dose in preterm infants correlated with a higher incidence of cerebellar injury and lower cerebellar diameter at term equivalent age. Our findings must be taken with caution, but emphasize the need for future prospective trials examining the risks and benefits of commonly used analgesic agents in preterm infants.
AB - Background: Fentanyl is commonly used in preterm infants. Relatively little is known regarding the neurodevelopmental outcomes of preterm infants exposed to fentanyl. Objective: To investigate the association between cumulative fentanyl dose and brain injury and diameters in a cohort of preterm infants. Methods: Data on demographics, perinatal course, and neonatal course, including total fentanyl exposure prior to term equivalent age, were retrospectively evaluated for 103 infants born at ≤30 weeks gestational age (mean gestational age 26.9 ± 1.8 weeks) who underwent magnetic resonance imaging at term equivalent age. Magnetic resonance images were evaluated for brain injury and regional brain diameters. Developmental testing was conducted at term equivalent and 2 years of age. Results: Seventy-eight infants (76%) received fentanyl (median cumulative dose 3 µg/kg, interquartile range 1-441 µg/kg). Cumulative fentanyl dose in the first week of life correlated with the incidence of cerebellar hemorrhage after correction for covariates (odds ratio 2.1, 95% confidence interval 1.1-4.1). Cumulative fentanyl dose before term equivalent age correlated with reductions in transverse cerebellar diameter after correction for covariates, including the presence of cerebellar hemorrhage (r = 0.461, P = 0.002). No correlation was detected between cumulative fentanyl dose and development at 2 years of age. Conclusions: Higher cumulative fentanyl dose in preterm infants correlated with a higher incidence of cerebellar injury and lower cerebellar diameter at term equivalent age. Our findings must be taken with caution, but emphasize the need for future prospective trials examining the risks and benefits of commonly used analgesic agents in preterm infants.
KW - analgesics
KW - magnetic resonance imaging
KW - neonatal intensive care
KW - opioid analgesics
KW - premature infant
UR - http://www.scopus.com/inward/record.url?scp=84947266479&partnerID=8YFLogxK
U2 - 10.1177/1060028015606732
DO - 10.1177/1060028015606732
M3 - Article
C2 - 26369570
AN - SCOPUS:84947266479
SN - 1060-0280
VL - 49
SP - 1291
EP - 1297
JO - Annals of Pharmacotherapy
JF - Annals of Pharmacotherapy
IS - 12
ER -